```html

Yervoy (ipilimumab)‑Related Colitis

Overview

Yervoy (ipilimumab) is a checkpoint‑inhibitor immunotherapy that blocks the CTLA‑4 protein on T‑cells, thereby boosting the body’s immune response against melanoma and other advanced cancers. While it can be life‑saving, the heightened immune activity can mistakenly attack normal tissues, most commonly the lining of the colon, leading to immune‑related colitis.

‑ **Who it affects:** Adults receiving ipilimumab for melanoma, renal cell carcinoma, or certain lung cancers. Colitis can appear after the first dose, but most cases arise after 2–3 treatment cycles (typically 6–12 weeks).
‑ **Prevalence:** Clinical trials report colitis in 8–10% of patients receiving the standard 3 mg/kg dose, with severe (grade ≥ 3) cases in ≈ 3% – 5%.<sup>1</sup> Real‑world registries show similar rates, though combinations with other checkpoint inhibitors (e.g., nivolumab) increase the risk to 15–20%.<sup>2</sup>

Symptoms

Symptoms can range from mild diarrhea to life‑threatening perforation. They often appear gradually but can progress quickly.

• Diarrhea – ≥ 3 loose stools per day; may be watery or contain mucus.
• Abdominal pain or cramping – Usually diffuse, sometimes sharp.
• Bloody stools – Indicates mucosal ulceration; a red flag.
• Urgency or incontinence – Loss of control over bowel movements.
• Nausea & vomiting – May accompany severe inflammation.
• Fever – Often ≥ 38 °C (100.4 °F), signaling systemic inflammation.
• Weight loss – From fluid loss and reduced intake.
• Fatigue – Common with any immunotherapy‑related adverse event.
• Rectal bleeding – May be isolated or part of generalized bleeding.

Causes and Risk Factors

Pathophysiology

Ipilimumab blocks CTLA‑4, a checkpoint that normally dampens T‑cell activation. Without this brake, autoreactive T‑cells infiltrate the colon, releasing cytokines (TNF‑α, IFN‑γ, IL‑17) that damage the mucosal lining, leading to colitis.

Risk Factors

• Higher ipilimumab dose – 10 mg/kg carries a 2–3‑fold higher colitis risk than 3 mg/kg.<sup>3</sup>
• Combination therapy – Adding PD‑1/PD‑L1 inhibitors (nivolumab, pembrolizumab) raises incidence.
• Pre‑existing autoimmune disease – E.g., inflammatory bowel disease (IBD) increases susceptibility.
• Age > 65 – Older immune systems may react more erratically.
• Female sex – Slightly higher rates reported in some series.
• Genetic factors – Polymorphisms in cytokine genes are under investigation.

Diagnosis

Diagnosis is primarily clinical, supported by laboratory and imaging studies to rule out infection or other causes.

Step‑by‑step approach

1. History & physical exam – Document stool frequency, blood, abdominal tenderness.
2. Stool studies – Culture, Clostridioides difficile PCR/toxin, ova & parasites to exclude infectious colitis.
3. Blood tests – CBC (look for anemia, leukocytosis), CRP/ESR (inflammation), electrolytes, renal function.
4. Endoscopy – Flexible sigmoidoscopy or colonoscopy with biopsies is the gold standard. Typical findings: erythema, loss of vascular pattern, ulcerations, and crypt abscesses.<sup>4</sup>
5. Imaging – Abdominal CT with contrast if perforation or severe colitis is suspected; may show bowel wall thickening.

Treatment Options

Treatment is graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Prompt management can prevent progression.

Grade 1 (mild) – monitor

• Continue ipilimumab if symptoms are ≤ 4 stools/day without blood.
• Increase oral hydration, use loperamide (anti‑diarrheal) as needed.
• Close follow‑up (every 48–72 h) with oncology team.

Grade 2 (moderate) – hold therapy, start steroids

• Withhold ipilumab.
• Prednisone 1 mg/kg/day orally (or equivalent). Taper over 4–6 weeks after symptoms improve.
• If no response within 48–72 h, consider adding infliximab (5 mg/kg IV) or vedolizumab (300 mg IV).

Grade 3–4 (severe) – hospitalization, high‑dose steroids, biologics

• Admit to a monitored unit.
• Methylprednisolone 1–2 mg/kg IV every 12 h.
• Early addition of infliximab (5 mg/kg, repeat in 2 weeks) is recommended unless contraindicated (e.g., active infection, TB).
• If infliximab fails or is contraindicated, use vedolizumab (gut‑selective) or mycophenolate mofetil.
• Surgical consultation for perforation, massive bleeding, or refractory disease.

Supportive Measures

• IV fluids + electrolyte replacement.
• Broad‑spectrum antibiotics only if bacterial infection is proven or strongly suspected.
• Nutrition: low‑residue diet initially; advance as tolerated.
• Probiotics – limited data, but may aid recovery in mild cases.

Living with Yervoy (ipilimumab)‑Related Colitis

Daily Management Tips

• Track bowel movements – Use a diary (frequency, consistency, blood).
• Hydration – Aim for ≥ 2 L water/day; oral rehydration solutions if losing electrolytes.
• Diet – Low‑fiber, low‑fat foods; avoid spicy, caffeine, alcohol, and dairy if lactose intolerant.
• Medication adherence – Take steroids exactly as prescribed; never stop abruptly.
• Stress reduction – Gentle walking, breathing exercises, or yoga (once pain permits) can help gut motility.
• Follow‑up appointments – Keep all oncology and gastroenterology visits; labs are usually checked weekly during steroid taper.
• Vaccinations – Discuss timing of flu and COVID‑19 vaccines, as steroids can blunt response.
• Know when to call – Persistent diarrhea > 7 days, new blood, fever, or abdominal swelling.

Prevention

While colitis cannot be completely prevented, risk can be minimized:

• Baseline screening – Review personal/family history of IBD before starting ipilimumab.
• Prophylactic budesonide – Small studies suggest oral budesonide (9 mg/day) may lower incidence in high‑risk patients; discuss with your oncologist.
• Avoid NSAIDs and antibiotics – Both can disrupt gut mucosa and microbiota.
• Early symptom reporting – Promptly tell the care team about any change in bowel habits.
• Vaccinate against C. difficile – Not yet widely available, but emerging vaccines may reduce infection‑related colitis.

Complications

If untreated or delayed, immune‑related colitis can lead to serious outcomes:

• Colonic perforation – Life‑threatening, requiring emergent surgery.
• Severe hemorrhage – May need transfusion or endoscopic hemostasis.
• Electrolyte disturbances – Hypokalemia, hyponatremia, leading to arrhythmias.
• Dehydration & acute kidney injury.
• Chronic bowel dysfunction – Strictures or persistent diarrhea after resolution.
• Impact on cancer therapy – Severe colitis often forces permanent discontinuation of ipilimumab, potentially limiting oncologic outcomes.

When to Seek Emergency Care

---

References

1. Wolchok JD, et al. Management of immune‑related adverse events in patients treated with ipilimumab. N Engl J Med. 2015;371: 824‑834. DOI:10.1056/NEJMoa1505275.
2. Postow MA, et al. Anti‑PD‑1 and anti‑CTLA‑4 therapy: toxicities, patterns, and management. Nat Rev Clin Oncol. 2020;17: 311‑322. DOI:10.1038/s41571-020-0401-2.
3. Larkin J, et al. Combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2015;373: 23‑34. DOI:10.1056/NEJMoa1504030.
4. Haanen JBAG, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2017;28: iv68‑iv78. DOI:10.1093/annonc/mdx187.

For personalized advice, always discuss symptoms and treatment plans with your oncology and gastroenterology teams.

```